PRN1008: BTK Inhibitor Autoimmune / Inflammatory Diseases

Phase 2

Bruton’s Tyrosine Kinase (BTK) is a protein important to the proper function of the immune system. BTK is a key part of the signaling pathway downstream of the B-cell and Fcγ receptors on most types of white blood cells except T-cells and plasma cells. Inhibition of BTK results in the down-regulation of various cellular activities that are activated in autoimmune and inflammatory diseases.

  • Ongoing Phase 2 clinical trial in patients with pemphigus vulgaris: 12-week open-label trial in naïve or relapsing patients

  • Ongoing Phase 2 clinical trial in patients with Immune Thrombocytopenic Purpura (ITP): 12-week open-label trial relapsed patients
  • Successful completion of Phase 1 trials. PRN1008 has been evaluated in over 100 healthy volunteers

  • BTK modulates immune cell signaling central to many components of autoimmune and inflammatory diseases